December 9, 2022 blogger Affinity, analysis, analytics, bio, Business, Business Analysis, cannabinoid, cannabis, Christina Diarcangelo, clinical, diabetic, drug, Federal, government, Growing, head, industry, lab, laboratories, laboratory, labs, Law, Legal, legalization, Legalize, legislation, license, marijuana, Medical, Medicial Marijuana, Medicine, nerve, pain, Partners, pharma, pharmaceutical, product, Product Development, quality, regulation, regulatory, safety, state, Stop Smoking Marijuana, Stop Smoking Pot, Studies, Study, test, Testing, therapeutics, to, trial, weed, withdrawal, Zelira
Affinity Bio Partners on Working with Zelira Therapeutics to Complete Enrolment for Diabetic Nerve Pain Drug Trial It’s an exciting time in the medical cannabis community as Zelira, a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, and Affinity Bio Partners, a leading, global clinical research organization, have completed enrollment […]
Affinity, analysis, analytics, bio, Business, Business Analysis, cannabinoid, cannabis, Christina Diarcangelo, clinical, diabetic, drug, Federal, government, Growing, head, industry, lab, laboratories, laboratory, labs, Law, legal, legalization, Legalize, legislation, license, marijuana, Medical, Medicine, nerve, pain, Partners, pharma, pharmaceutical, product, Product Development, quality, regulation, regulatory, safety, state, Studies, Study, test, Testing, therapeutics, to, trial, Zelira